Wordt geladen...

Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study

Bendamustine + rituximab (BR) has demonstrated high response rates in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). However, progression-free survival (PFS) after BR is <18 months. This study was designed to determine if maintenance lenalidomid...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Br J Haematol
Hoofdauteurs: Chang, Julie E., Havighurst, Thomas, Kim, KyungMann, Eickhoff, Jens, Traynor, Anne M., Kirby-Slimp, Rachel, Volk, Lynn M., Werndli, Jae, Go, Ronald S., Weiss, Matthias, Blank, Jules, Kahl, Brad S.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2016
Onderwerpen:
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5923897/
https://ncbi.nlm.nih.gov/pubmed/26913697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13957
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!